Nicholas Draeger
Founder and Director at Cederberg GmbH, Basel area, Switzerland
Studied Chemical Engineering at the University of Natal in Durban, South Africa, and moved to Cambridge, UK, to research for a PhD in Biochemical Engineering focusing on protein and peptide purification and characterisation. Later, studied for an MBA from the Warwick Business School, UK, while working at Roche in Switzerland.
Moved to Basel, Switzerland, in 1992 for career at Roche, initially as a research scientist in the genetic engineering department focusing on neurodegenerative diseases and HIV, and then as a member of the Global Business Development Department of the Pharmaceutical Division, focusing on in-licensing and M&A. Subsequently moved to be Director of Business Development at Recordati in Italy.
From 2000 headed the Biotech Research Team on the sell-side of Credit Agricole Indosuez Cheuvreux, based in Zurich in Switzerland, and was Scientific Coordinator of the Healthcare Team. Then moved to the buy-side as member of the BB Biotech management team in Zurich and subsequently joined Adamant Biomedical Investments in December 2003, as Partner and Portfolio Manager, focusing on biotech, pharma and specialty pharma (especially in the emerging markets).
Founded Cederberg, an international healthcare company headquartered in Switzerland, Valevia Pharmaceuticals, a company focused on R&D in the anti-infectives sector, and Nurevas International for the production of food products in sub-saharan Africa.
Specialties: Starting and building companies in various sectors and international Business Development with a particular focus on M&A.